deep leaning

Views & Analysis

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

News

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.